ClinicalTrials.gg
Not yet recruitingNCT07641231RAPID-STEMIUpdated Jun 11, 2026

Reperfusion Approach in Predicted In-hospital Delay for Primary PCI in STEMI

A Phase 4 interventional study of Single, weight-adjusted i.v. bolus of tenecteplase and catheterisation in STEMI - ST Elevation Myocardial Infarction, sponsored by National Medical Research Center for Cardiology, Ministry of Health of Russian Federation. Not yet recruiting at 1 site in Russia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by National Medical Research Center for Cardiology, Ministry of Health of Russian Federation · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study aims at evaluating of the effectiveness of in-hospital thrombolysis for ST-segment elevation myocardial infarction in PCI centers under conditions of predicted in-hospital delay (>60 min after admission in PCI-center) of PCI. Following randomisation a strategy of early tenecteplase and additional antiplatelet and antithrombin therapy followed by catheterisation within 2-24 hours with timely coronary intervention as appropriate (or by rescue coronary intervention if required) in Group A will be compared to primary PCI performed according to local standards in Group B.

02

Conditions studied

  • STEMI - ST Elevation Myocardial Infarction

Keywords

  • in-hospital fibrinolysis
  • STEMI
  • pharmacoinvasive strategy
  • myocardial infarction (MI)
  • thrombolysis
03

In context

ST Elevation Myocardial Infarction

855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.

This study's planned enrollment of 240 is above the median of 194 across 531 interventional studies indexed under ST Elevation Myocardial Infarction.

Browse ST Elevation Myocardial Infarction studies →

Lead sponsor

National Medical Research Center for Cardiology, Ministry of Health of Russian Federation is the lead sponsor of 20 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age equal or greater than 18 years
  • "Symptom onset-randomization" time interval \<12 hours
  • Predicted "diagnosis-pPCI" time interval equal or greater than 120 minutes
  • Predicted "admission-pPCI" time interval equal or greater than 60 minutes
  • received

Exclusion criteria

Exclusion Criteria:

  • Medical history, procedures, medication administration or the presence of factors that would in general predispose to bleeding events and/or the inability to evaluate the study primary endpoint
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    In-hospital thrombolysis in PCI-center

    In-hospital thrombolysis with tenecteplase in case of predicted delayed pPCI (\>60 min after admission in PCI-center). Early tenecteplase, clopidogrel and enoxaparin followed by routine or rescue coronary intervention.

    Drug: Single, weight-adjusted i.v. bolus of tenecteplase · Procedure: catheterisation

  • Active comparator
    Primary PCI in PCI-center

    Standard primary PCI in case of predicted delayed pPCI (\>60 min after admission in PCI-center).

    Procedure: catheterisation

Interventions

  • DrugSingle, weight-adjusted i.v. bolus of tenecteplase

    Single, weight-adjusted i.v. bolus of tenecteplase in case of \>60 min in-hospital delay in PCI center

  • Procedurecatheterisation

    Standard primary PCI

    Also known as: Routine or rescue coronary intervention

06

What researchers measure

Primary outcomes

  1. The number of observed patients with cardiovascular death, nonfatal stroke, and nonfatal AMI within 12 months for FAS.

    Participants achieved a response if they have cardiovascular death or nonfatal stroke, or nonfatal AMI at 12 months.

    Time frame: From enrollment to the end of follow-up (12 months).

Secondary outcomes

  1. Number of patients with all-cause mortality

    Time frame: during hospitalization (assessed up to 10 days)

  2. Number of patients with cardiovascular mortality

    Time frame: during hospitalization (assessed up to 10 days)

  3. Number of patients with non-fatal MI

    Time frame: during hospitalization (assessed up to 10 days)

  4. Number of patients with hemorrhagic stroke

    Time frame: during hospitalization (assessed up to 10 days)

  5. Number of patients with major bleeding according to the BARC scale (type 3-5)

    Time frame: during hospitalization (assessed up to 10 days)

  6. Number of patients with non-fatal complications of MI (AHF, cardiogenic shock, arrhythmias, MI, mechanical complications, thromboembolic complications )

    Time frame: during hospitalization (assessed up to 10 days)

  7. Number of patients with all-cause mortality

    Time frame: 12 months

  8. Number of patients with cardiovascular mortality

    Time frame: 12 months

  9. Number of patients with non-fatal MI

    Time frame: 12 months

  10. Number of patients with hemorrhagic stroke

    Time frame: 12 months

  11. Number of patients with major bleeding according to the BARC scale (type 3-5)

    Time frame: 12 months

  12. Number of patients with non-fatal complications of MI (AHF, cardiogenic shock, arrhythmias, MI, mechanical complications, thromboembolic complications)

    Time frame: 12 months

07

Study locations

1 site
  • National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
    Moscow, Select A State 121552, Russia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for May 2028, 24 months later.

Of 44 non-industry phase 4 interventional studies under ST Elevation Myocardial Infarction, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 74. This study's planned 24 months is below that.

Counting every sponsor, half of 49 studies reached it within 34 months; a quarter within 22 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2026
First posted
Jun 11, 2026
StartEst.
May 20, 2026
Primary completionEst.
May 20, 2028
CompletionEst.
May 20, 2029
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07641231
Lead sponsor
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Collaborators
AO GENERIUM
Responsible party
Dmitry Pevzner (Doctor of Medical Sciences, Professor, Head of the Emergency Cardiology Department, National Medical Research Center for Cardiology, Ministry of Health of Russian Federation) — Principal investigator
First posted
Jun 11, 2026
Start date
May 20, 2026 (estimated)
Primary completion
May 20, 2028 (estimated)
Completion
May 20, 2029 (estimated)
Last update
Jun 11, 2026

Study contacts

Rimma Gulyan
Contact
rimmagulyan5@mail.ru
+79152284043
Dmitry Pevzner, Doctor of Medical Sciences
study director · National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Rimma Gulyan
principal investigator · National Medical Research Center for Cardiology, Ministry of Health of Russian Federation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion